OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Bekaii-Saab on the Potential Impact of Napabucasin Combo in Pancreatic Cancer

July 13th 2017

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the potential impact of the combination of napabucasin with gemcitabine and nab-paclitaxel in pancreatic cancer.

Dr. Lenz Discusses Targeted Combinations in Colorectal Cancer

July 13th 2017

Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses combinations with targeted agents in colorectal cancer.

Dr. Klein on Precision Medicine for Prostate Cancer

July 13th 2017

Eric Klein, MD, professor of Surgery, Lerner College of Medicine, Cleveland Clinic, discusses precision medicine in patients with prostate cancer.

Dr. Petrylak on Combinations with Pembrolizumab in Urothelial Carcinoma

July 13th 2017

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.

Dr. Burstein on the Results of the APT Trial for HER2+ Breast Cancer

July 13th 2017

Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the results of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.

Dr. Hellmann on the Design of the CheckMate-032 Study for Lung Cancer

July 13th 2017

Matthew D. Hellmann, MD, Memorial Sloan Kettering Cancer Center, discusses the design of the CheckMate-032 study investigating nivolumab (Opdivo) with or without ipilimumab (Yervoy) for patients with small cell lung cancer (SCLC).

Dr. Voorhees on Pivotal Ongoing Trials in Multiple Myeloma

July 12th 2017

Peter Voorhees, MD, hematology, medical oncology, Carolinas HealthCare System, discusses pivotal ongoing clinical trials in the field of multiple myeloma.

Dr. Chowdhury on Separate Roles of Pazopanib and Pembrolizumab in RCC

July 12th 2017

Simon Chowdhury, MA, MBBS, MRCP, PhD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses what roles pazopanib (Votrient) and pembrolizumab (Keytruda) have as monotherapy for patients with renal cell carcinoma (RCC).

Dr. Tilly Discusses Study of POLA-R-CHP in DLBCL

July 12th 2017

Herve Tilly, MD, PhD, Centre Henri Becquerel, discusses a study of polatuzumab vedotin combined with rituximab (Rituxan), cyclophosphamide, doxorubicin and prednisone (PLOA-R-CHP) in patients with previously untreated diffuse large B-cell lymphoma.

Dr. Parikh on the Applicability of Liquid Biopsies in Gastrointestinal Cancers

July 12th 2017

Aparna R. Parikh, MD, medical oncologist, Massachusetts General Hospital, discusses the applicability of liquid biopsies in gastrointestinal cancers.

Dr. Balar on the Approval of Pembrolizumab for Bladder Cancer

July 11th 2017

Arjun V. Balar, MD, assistant professor of medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the approval of pembrolizumab (Keytruda) in bladder cancer.

Dr. Loeb on Determining Beneficial Test Options for Prostate Cancer

July 11th 2017

Stacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses how to determine which test will be beneficial for the management of prostate cancer.

Dr. Agarwal on Potential Agents for Metastatic Hormone-Sensitive Prostate Cancer

July 11th 2017

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses potential agents for the treatment of patients with metastatic hormone-sensitive prostate cancer.

Dr. Siegel on Results of Chemotherapy and Transoral Surgery Study for Head and Neck Cancer

July 11th 2017

Robert Siegel, MD, chair, professor of medicine, director, Division of Hematology/Oncology, George Washington University, discusses a phase II study investigating induction chemotherapy and transoral surgery for patients with head and neck cancer.

Dr. Shah on CAR T-cell Therapy's Effectiveness in ALL

July 11th 2017

Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, explains why chimeric antigen receptor (CAR) T-cell therapy has shown the most progress in acute lymphoblastic leukemia (ALL).

Dr. Garcia on Sequencing Immunotherapies in Bladder Cancer

July 11th 2017

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the optimal sequence of immunotherapies for the treatment of patients with bladder cancer.

Dr. Pinato Discusses Pheochromocytomas and Paragangliomas

July 10th 2017

David J. Pinato, MD, PhD, NIHR Academic Clinical Lecturer in Medical Oncology, resident, Royal Brompton Hospital and Imperial College London, discusses pheochromocytomas and paragangliomas.

Dr. O'Neil on Next Steps for Napabucasin With FOLFIRI and Bevacizumab in CRC

July 10th 2017

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the next steps for napabucasin with FOLFIRI and bevacizumab (Avastin) as treatment for patients with colorectal cancer.

Dr. Bruix Discusses Progress of Second-Line Treatment in HCC

July 10th 2017

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the impact of the recent progress in the second-line treatment setting for hepatocellular carcinoma.

Dr. Levine on the PARP Inhibitor Landscape for Ovarian Cancer

July 7th 2017

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses the PARP inhibitor landscape for patients with ovarian cancer.